Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metazocine SCHEMBL13353229 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL21994208 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL12013732 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL1649365 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL12049577 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL26347 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL15866689 | 0.92 | SIGMAR1 (0.85) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12267534 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12324824 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12716235 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| CN-119818470-A | Pharmaceutical composition containing melagatran besylate and preparation method thereof | 齐鲁制药(海南)有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |